Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Ovarian Cancer Clinical Oncology

  • Maurie Markman
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6953-2


Ovarian cancer is a malignant neoplasm involving the ovaries. The majority of ovarian cancers consist of epithelial ovarian cancer (Ovarian Cancer Pathology). Treatment of primary cancers of the peritoneum and fallopian tube is generally quite similar (if not identical) to that of epithelial ovarian cancer.


Natural History

In striking contrast to endometrial cancer and cervical cancer, which together with ovarian cancer are responsible for the large majority of female pelvic malignancies, more than 70 % of women with ovarian cancer present with malignant cells documented to be outside the confines of the organ of origin. Further, the cancers in more than 60 % of this population exhibit high-grade histologic features (Ovarian Cancer Pathology), a pattern very different from that of uterus cancer or cervical cancer. These two factors are clinically relevant and have important unfavorable implications for the opportunity to achieve long-term control of the...


Ovarian Cancer Epithelial Ovarian Cancer Ovarian Cancer Patient Advanced Ovarian Cancer Surgical Cytoreduction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Audeh MW, Carmichael J, Penson RT et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376:245–251CrossRefPubMedGoogle Scholar
  2. Hennessy B, Coleman RL, Markman M (2009) Ovarian cancer. Lancet 374:1371–1382CrossRefPubMedGoogle Scholar
  3. Katsumata N, Yasuda M, Takahashi F et al (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial. Lancet 374:1331–1338CrossRefPubMedGoogle Scholar
  4. Liu JF, Konstantinopoulos PA, Matulonis UA (2014) PARP inhibitors in ovarian cancer: Current status and future promise. Gynecol Oncol 133:362–369Google Scholar
  5. Markman M, Walker JL (2006) Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 24:988–994CrossRefPubMedGoogle Scholar
  6. Pujade-Lauraine E, Hilpert F, Weber B et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302–1308Google Scholar
  7. Vergote O, Trope CG, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 336:943–953CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Medical OncologyEastern Regional Medical CenterPhiladelphiaUSA